Cytokinetics Collaborating With Origent Data Sciences To Refine Model Of ALS Disease …

Cytokinetics (NASDAQ:CYTK), a biopharmaceutical company, has disclosed plans to collaborate with Origent Data Sciences, a privately-held predictive technology company, to refine an Origent computer model to predict the course of ALS disease progression. The research collaboration will use data from Cytokinetics’ clinical trials of tirasemtiv and will be funded by Origent’s grant from The ALS Association. The research will enable the first prospective validation of the predictive model in a clinical trial setting, the companies said. Previously, the Origent models predicting both function and survival of ALS patients have been validated using internal and retrospective external datasets. “If validated, the models we have developed will be submitted to the FDA and may enable more nimble, cost-effective execution of ALS clinical trials, resulting in a potentially quicker path to new medicines,”…


Link to Full Article: Cytokinetics Collaborating With Origent Data Sciences To Refine Model Of ALS Disease …